Generic versions of GLP-1 drugs — the class of weight-loss medications that includes Ozempic — are gaining attention in India as a possible tool to address the country's growing obesity crisis, which carries serious health implications beyond body size. Early users report significant weight loss and improved metabolic health; one Mumbai-based television producer described losing 22 kg in roughly six weeks after starting the treatment, having previously been classified as pre-diabetic. If made widely accessible at lower cost through generic formulations, the drugs could represent a significant shift in how India manages obesity-related conditions such as type 2 diabetes and cardiovascular disease.